83Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Argentina
Neuroscience Intelligence
Argentina neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #28 of 50 · Data maturity A · Research score 34.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
29Recruiting trials
19Publications
49Institutions
Executive interpretation
Argentina ranks #28 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Hoffmann-La Roche114 recruiting
Merck Sharp & Dohme LLC95 recruiting
Pfizer50 recruiting
Novartis Pharmaceuticals41 recruiting
Novo Nordisk A/S42 recruiting
Eli Lilly and Company41 recruiting
GlaxoSmithKline40 recruiting
Washington University School of Medicine33 recruiting
Bayer22 recruiting
Amgen21 recruiting
Disease activity
Alzheimers19trials
Parkinsons10trials
Epilepsy8trials
Schizophrenia6trials
Depression4trials
Other Neurology3trials
Multiple Sclerosis3trials
Neuromuscular3trials
Als2trials
Migraine Headache2trials
Research institutions
Instituto de Física de Buenos AiresOpenAlexlinked institution
Hospital Universitario AustralOpenAlexlinked institution
Sanatorio Otamendi y MiroliOpenAlexlinked institution
Universidad de MorónOpenAlexlinked institution
National University of Mar del PlataOpenAlexlinked institution
Instituto de Neurología CognitivaOpenAlexlinked institution
Instituto Universitario de Ciencias de la Salud - Fundación Héctor A. BarcelóOpenAlexlinked institution
Universidad Torcuato Di TellaOpenAlexlinked institution
Universidad Nacional del LitoralOpenAlexlinked institution
Fundación Ciencias Exactas y NaturalesOpenAlexlinked institution
Clinical evidence trail
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
Research evidence trail
PUBMEDWWOX-related developmental and epileptic encephalopathy (WOREE): A case series of seven patients from Argentina.2026-11-01
PUBMEDDisrupted emotional neural synchrony in schizophrenia revealed by intersubject correlation of naturalistic fMRI.2026-10-01
PUBMEDRadiosurgical management of trigeminal neuralgia; Differences in outcomes between proximal and distal targeting: Meta-analysis of 1055 patients.2026-09-19
PUBMEDBetaII-spectrin gaps and patches emerge from the patterned assembly of the actin/spectrin membrane skeleton in human motor neuron axons.2026-09-08
PUBMEDLong-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol.2026-09-01
PUBMEDEarly predictors for later epilepsy after therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy.2026-09-01
PUBMEDEarly ethanol exposure during gestation and lactation disrupts gut integrity and enhances ethanol intake in C57BL/6 mice offspring.2026-09-01
PUBMEDFrom Severe Neonatal Encephalopathy to Slowly Neurologic Progressive Disease: Pyruvate Dehydrogenase Deficiency Related to PDHA1 Variants.2026-09-01
OPENALEXNeuroinflammation: An Integrating Overview of Reactive‐Neuroimmune Cell Interactions in Health and Disease2021-01-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.